CME Symposium on Cardiovascular Outcome Trials and Expert Consensus Decision Pathways: Interpreting the Evidence with Nonstatin Therapies

SPRINGFIELD, N.J. - March 22, 2018 - PRLog -- Cardiovascular Outcome Trials and Expert Consensus Decision Pathways: Interpreting the Evidence with Nonstatin Therapies

Robert Giugliano, MD, SM (Chair)
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Christie Ballantyne, MD
Professor of Medicine
Baylor College of Medicine
Houston, Texas

Eliot Brinton, MD
President
Utah Lipid Center
Salt Lake City, Utah

Joseph Saseen, PharmD
Professor, Departments of Clinical Pharmacy and Family Medicine
University of Colorado School of Pharmacy
Aurora, Colorado

Peter Toth, MD, PhD
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, Illinois

Click to Register Online

The knowledge base on the use of non-statin therapies for LDL-C lowering has rapidly increased with the release of primary results and secondary analyses from cardiovascular outcome trials (CVOTs). The ongoing presentation and publication of evidence from the IMPROVE-IT and FOURIER trials has created a need for lipidologists to be informed of this information which may have a significant impact on their clinical practice. Furthermore, an assessment of the ODYSSEY OUTCOMES trial, presented at ACC 2018, and a comparison/contrast of the FOURIER and ODYSSEY OUTCOMES trials are needed to assist lipidologists with clinical decision-making regarding prudent use of PCSK9 inhibitors. As a result, best practice is rapidly evolving with non-statin therapies, necessitating the release of updated recommendations from the NLA on the use of PCSK9 inhibitors, new dyslipidemia guidelines from the AACE/ACE, and a focused update of the ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk. In this symposium, chair Dr. Robert Giugliano, and faculty members Dr. Christie Ballantyne, Dr. Eliot Brinton, Dr. Joseph Saseen, and Dr. Peter Toth will provide updates to landmark CVOTs, engage in a lively and insightful panel discussion of the FOURIER and ODYSSEY OUTCOMES trials, describe the impact of emerging data on clinical practice, provide recommendations for the use of non-statin therapies, and identify key issues in the development of new guidelines.

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association and Voxmedia LLC. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The National Lipid Association designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Universal Activity Number - J0007192-9999-18-004-L01-P (Application)This Activity has been approved for 2.00 contact hour(s) (.2 CEUs) of the Accreditation Council for Pharmacy Education.

The maximum number of hours awarded for this CE activity is 2.0 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

This activity is supported by an educational donation provided by Amgen.

Pre-registration is for planning purposes only.
For additional CME activities and online CME courses, visit CMEPlanet.